Toronto, Ontario – October 17, 2012 -- Theralase
Technologies Inc. (TSX-V: TLT) announced
today that its Photo Dynamic Compound (PDC) technology has been proven effective
in the destruction of staphylococcus
aureus and its multi drug resistant strain, methicillin resistant
staphylococcus aureus, also known as MRSA.
MRSA
is a bacteria strain that has grown resistant to antibiotics and hence has the
potential of causing invasive infections, which are extremely difficult to
treat in 25% of the population infected. In 2005, the Centers for Disease Control and
Prevention
reported that 94,000 individuals
were hospitalized as a result of MRSA infections and there were 18,650 deaths as
a result, costing the US healthcare system an additional $45 billion a year.
The scientific data supporting
this discovery was presented yesterday at the 9th International
Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held
in Brixen, Italy. The presentation by Dr. Lothar Lilge confirms the significance
of the research conducted by Theralase’s and University Health Network’s (UHN) scientists.
Dr. Arkady Mandel, Chief
Scientific Officer of Theralase Inc. stated that, “Theralase unveiled to the
scientific community its advanced sterilization platform technology that is able
to deliver an 8 log or 99.999999% kill rate, which is comparable with complete sterilization of life threatening infectious microorganisms, such as staphylococcus aureus
and MRSA. Theralase’s new PDC technology
would therefore be well suited to preventing hospital acquired infections, as
well as infections found in nursing homes, schools or bacterial contaminations in
food processing facilities. Quite simply, once MRSA bacteria have been detected,
they could be quickly destroyed utilizing Theralase’s patented Photo Dynamic
Compounds and proprietary light sources.”
Dr. Lothar
Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre,
UHN stated, “Theralase’s PDCs in conjunction with light exposure were shown to
achieve essentially complete sterilization, even at low concentrations, against
staphylococcus aureus and MRSA in an in
vitro laboratory setting. The
effective dose of tested PDCs was not toxic for human tissues even after 4
hours of incubation demonstrating their suitability and safety to sterilization
applications. As an added benefit, the Theralase PDCs maintained their
sterilizing activity even in low oxygen conditions demonstrating a Type I
photosensitization effect that may open up new opportunities for the safe and effective
destruction of many strains of deadly organisms and tumours that thrive in low
oxygen environments, such as cancer.”
Dr. Arkady Mandel went on to say, “The dramatic increase of antibiotic
resistance in bacteria has led me to investigate whether Theralase’s PDCs would
be effective in the destruction of MRSA, as an alternative to antibacterial pharmaceutical
drugs. Our successes to date will allow Theralase’s
PDCs to be used in the future to combat difficult to heal invasive infections. The Theralase PDCs in these studies
have been chosen for their low dark toxicity to human tissue and for their high
cancer and bacteria targeting properties. The Theralase PDCs are extremely promising
for the development of advanced disinfection and sterilization strategies for controlling
and eliminating hospital and community acquired infections, such as MRSA.”
Roger Dumoulin-White,
President and CEO of Theralase stated, “Based on our recent successes with our
PDC technology in destroying MRSA, Theralase is actively pursuing early
commercialization of this technology through strategic partnerships to
co-develop the technology for particular sterilization applications. As an
added benefit, due to the very low concentrations of PDCs required for
sterilization, the costs of administering this technology will be very cost
effective. The early commercialization of our patented PDC technology with
strategic partners will dramatically improve the financial revenues of the
organization. These scientific studies thus highlight Theralase’s commitment to
advancing its exclusive patented technologies for the ultimate goal of greater commercial
opportunities for the Company.”
Theralase Technologies Inc.,
founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction
applications. Theralase technology is safe and effective in treating pain,
inflammation and for tissue regeneration of neural muscular skeletal conditions
and wound healing. Theralase is currently developing patented Photo Dynamic
Compounds (PDCs) that are able to target and destroy cancers, bacteria and
viruses when light activated by Theralase’s proprietary and patented laser
technology.
For further information
please visit www.theralase.com, regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements,
which reflect the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The Company disclaims any
obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the TSX Venture
Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & Chief Executive Officer
416-447-8455 ext. 225
Nice work done... You have shared very good information..
ReplyDeleteSkin cancer is the most prevalent of all types of cancers. However, various methods of skin cancer treatment have emerged to eradicate this disease. You can visit Skin Cancer Treatment in Alabama
to get detailed information..